Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing ...
Paper in Frontiers in Immunology Describes Trimer Design and Development of Production CHO Cell Lines That Generate Properly Folded HIV-1 Env Trimers to Support Goal of Developing an Effective HIV ...
The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.
JSR will be providing the equity capital for OPM Asia that will enable the establishment of a world-class biomedical manufacturing and market development operation.
Crown Bioscience enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
Crown Bioscience announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the d...
